Blog

Company News

Industry Trends

Laws Regulations

All Categories >

22

2026-06

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)

The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.

2026-06-22

He Yousheng

09

2026-06

A Fresh Start, A New Beginning | Hycells’s Brand Identity Fully Reimagined

Every step forward is aimed at fulfilling our mission even more effectively.

2026-06-09

He Yousheng

02

2026-06

Focused on peptide immunogenicity assessment, precisely empowering tumor neoantigens.

In the field of cancer immunotherapy, tumor neoantigen–specific T-cell responses serve as a key metric for assessing peptide immunogenicity. Leveraging its well-established in vitro assay platform, Hycells Biotechnology offers end-to-end services—ranging from initial screening of peptide immunogenicity and antigen‑specific T-cell expansion to validation of tumor cell‑killing activity—thereby supporting the efficient and reliable discovery and validation of neoantigens.

2026-06-02

He Yousheng

25

2026-05

Pioneering a New Direction in Cell Therapy—The “Procedures for the Collection, Isolation, Culture, Preparation, and Quality Control of Human Peripheral Blood–Derived Natural Killer Cells,” co-authored by Hycells, Has Been Officially Released.

Recently, the draft jointly prepared with the participation of Shanghai Hycells Biotechnology Co., Ltd. Procedures for the Collection, Isolation, Culture, Preparation, and Quality Control of Natural Killer Cells Derived from Human Peripheral Blood The group standard has been officially released. Its introduction marks a solid and pivotal step forward in the standardized and regulated development of natural killer (NK) cell therapy in China.

2026-05-25

He Yousheng

10

2026-04

Training Announcement | Standardized System Training Course on Cell Therapy Manufacturing and Clinical Translation

This training program focuses on the regulatory standards governing the manufacturing of cell therapy products and the clinical research and translational applications of cutting-edge biomedical technologies, attracting participants from enterprises, research institutes, clinical institutions, and industry-chain representatives across the country. Standardization is the fundamental cornerstone for ensuring that these products are safe, effective, and accessible. As a one-stop upstream cell solutions provider offering primary cell services, pharmacological efficacy services, and product services, Heyousheng looks forward to engaging in in-depth exchanges with industry experts and peers.

2026-04-10

He Yousheng

10

2026-04

3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 3: CBNK Competitor Comparison

HeYouSheng Bio’s 3.0 High-Efficiency HiXpan® NK Serum-Free Culture Kit is manufactured in strict compliance with GMP standards, and its production system adheres to relevant guidelines, including the “818 Requirements,” making it suitable for pharmaceutical-grade manufacturing and applications. In response to extensive customer demand, we have conducted a comparative analysis of culture performance against two leading commercial competitor media.

2026-04-10

He Yousheng
< 1234...18 >